In Practice: Upcoming insulin supply changes and GP updates
18 Dec 2025
Manufacturer Eli Lilly has confirmed that vial formulations of both insulins will be gradually phased out starting from mid-2026.
From June 2026, only cartridge versions of Humulin and Humalog will continue to be available, and vial products are expected to be completely removed from the Australian market by 1 August 2026.
The Therapeutic Goods Administration (TGA) has updated the status of these products to reflect a decrease in supply until existing stock is fully used up.
For more details on the discontinuation, you can refer to the TGA’s medicine shortages and discontinuations listings.
Update from the Department of Veterans’ Affairs
The Department of Veterans’ Affairs (DVA) has announced that authorised psychiatrists can seek funding to provide psychedelic-assisted psychotherapy using MDMA or psilocybin for eligible veterans suffering from certain mental health conditions.
An on-demand recording of a clinician briefing held on 30 October is now available through DVA Provider News, which outlines eligibility criteria, approval processes, and clinical aspects related to this treatment.
GP Research Noticeboard opportunities
The GP Research Noticeboard continues to share research studies that require GP involvement.
Current projects include:
- Management of reproductive-age patients prescribed antiseizure medications
GPs are also encouraged to submit their own research projects to the Noticeboard to recruit participants from the general practice community.
Source:
Therapeutic Goods Administration (TGA); Department of Veterans’ Affairs (DVA) Provider News; RACGP GP Research Noticeboard.
